This year’s ASCO might have been overshadowed somewhat by the COVID-19 pandemic, but the now-virtual conference didn’t pull any punches, demonstrating that while coronavirus might be front and centre of everyone’s minds, the desire to see real change in cancer treatment hasn’t diminished.
In this issue, Jennifer Harris from Syneos Health discusses the biggest takeaways from the conference with Richard Staines. You can also read our full coverage of the event on pharmaphorum.com.
We also look beyond ASCO to get views from several cancer experts – including contributors from GSK, Accenture, ICON and Advanced Clinical – on how they think the future of oncology will play out.
They cover a wide range of topics, but it’s clear that they agree on several things – namely that the future of oncology research will be dominated by collaboration, innovative trials, and earlier planning. And that’s not to mention their shared excitement surrounding approaches like immuno-oncology and cell & gene therapy.
Finally, several of our contributors also analyse how COVID-19 is affecting cancer trials, and what the industry can do to solve these issues.
I hope you’re all staying safe in these unpredictable times!
George Underwood – editor, Deep Dive